Preparation and characterization of protocatechuic acid sulfates

Article abstract of DOI:10.3390/molecules24020307

Protocatechuic acid (3,4-dihydroxybenzoic acid; PCA) is a phenolic acid present in plants as a secondary metabolite and is also produced in the human organism as a metabolite from the degradation of polyphenols by the intestinal microbiota, particularly o

Full text of DOI:10.3390/molecules24020307

molecules
Article
Preparation and Characterization of Protocatechuic
Acid Sulfates
Sofia M. Gutierrez-Zetina, Susana Gonzalez-Manzano, Jose J. Perez-Alonso,
Ana M. Gonzalez-Paramas and Celestino Santos-Buelga *
Grupo de Investigación en Polifenoles, Unidad de Nutrición y Bromatología, Facultad de Farmacia, Universidad
de Salamanca, Campus Miguel de Unamuno, 37007 Salamanca, Spain; sofia_martinez@usal.es (S.M.G.-Z.);
susanagm@usal.es (S.G.-M.); josejpa@usal.es (J.J.P.-A.); paramas@usal.es (A.M.G.-P.)
* Correspondence: csb@usal.es; Tel.: +34-9-23-29-45-37
ꢀꢁꢂꢀꢃꢄꢅꢆꢇ
ꢀꢁꢂꢃꢄꢅꢆ
Academic Editors: Federica Pellati, Laura Mercolini and Roccaldo Sardella
Received: 21 December 2018; Accepted: 13 January 2019; Published: 16 January 2019
Abstract: Protocatechuic acid (3,4-dihydroxybenzoic acid; PCA) is a phenolic acid present in plants
as a secondary metabolite and is also produced in the human organism as a metabolite from the
degradation of polyphenols by the intestinal microbiota, particularly of flavonoids. However, PCA,
like most polyphenols, is biotransformed in the human body to different conjugates as sulfates,
which are found circulating in blood and could be involved in the bioactivity of the original compound.
This paper describes a simple process for the preparation of PCA monosulfates with satisfactory yields.
Two compounds were obtained that were identified as PCA-3-sulfate and PCA-4-sulfate by mass
spectrometry and 1H and 13C nuclear magnetic resonance using one- and two-dimensional techniques
(heteronuclear single-quantum coherence and heteronuclear multiple-bond correlation). Differential
MS fragmentation behavior and UV spectra were observed for each compound, which could be used
for their identification in samples of unknown composition. The described procedure can be used for
the preparation of these polyphenol metabolites in view of their use in in vivo and in vitro studies,
as well as standards for their analysis in biological fluids, to contribute to the elucidation of biological
effects of dietary polyphenols.
Keywords: polyphenols; phenolic metabolites; phase II conjugates; phenolic acids; sulfates;
hemisynthesis; identification
1. Introduction
Most polyphenols are poorly absorbed and largely biotransformed in the human body, either by
phase I and II enzymes of the metabolism or by gut microbiota, so that metabolites represent the main
circulating forms of dietary polyphenols in the organism and may ultimately be responsible for the
reported bioactivity of the original compounds [
the gut, where they interact with the microbiota and can be degraded to a range of products that may
be bioactive [ ]. As a matter of fact, the concentrations in plasma and urine of microbial phenolic
metabolites are normally higher than those of the metabolites derived from polyphenols uptake in
the stomach or small intestine [ ]. In general, phenolic sulfates have been indicated as abundant
1]. Most of the consumed polyphenols usually reach
2–4
5–9
metabolites of polyphenols in human plasma [10].
Protocatechuic acid (3,4-dihydroxybenzoic acid; PCA) is a phenolic acid present in plants as a
secondary metabolite produced through the shikimic acid pathway [11]. As such, it is commonly
found in fruits, vegetables, grains and spices, such as grapes, berries, onions, brown rice, rosemary,
and cinnamon, among others [12]. PCA is also produced in the human organism as a metabolite
from the degradation of polyphenols by the intestinal microbiota, particularly of flavonoids like
anthocyanins, flavonols or procyanidins [13]. It may be absorbed through the intestinal epithelium and
Molecules 2019, 24, 307; doi:10.3390/molecules24020307
www.mdpi.com/journal/molecules

Molecules 2019, 24, 307
2 of 9
reach systemic circulation. After uptake, PCA undergoes structural modifications through conjugation
processes, mostly occurring in the liver, giving rise to sulfated and glucuronidated forms that can be
distributed to the tissues, recycled back to the intestine, or excreted in urine [14
have been detected in relevant concentrations in plasma, urine, and feces after consumption of
polyphenol-rich diets [ 10 16]. Concentrations of phase II conjugates (sulfates + glucuronides) of PCA
up to 5,540 490 nM were determined in urine by Czank et al. [ ] following consumption of 500 mg of
13C-labelled cyanidin-3,O-glucoside by healthy humans, reaching maximum level 24 h after intake.
In the same intervention study, maximum concentrations of PCA sulfates of 157 116 nM were found
in serum with a tmax of 11.4 3.8 h, while maximum urinary concentrations of 1112 318 nM and
1244 333 nM were found for PCA-3-sulfate and PCA-4-sulfate, respectively, 1–2 h after anthocyanin
intake [ ]. Both sulfates were also detected in feces with maximum recoveries of 30.0 27.7
(PCA-3-sulfate) and 23.0 18.1 g (PCA-4-sulfate) at 6–24 h post-bolus from 500 mg of anthocyanidin
consumption [ ]. De Ferrars et al. [ ] found that PCA sulfates constituted the main group of phenolic
,15]. PCA conjugates
7–
,
±
7
±
±
±
±
9
±
µg
±
µ
9
8
metabolites in plasma, representing 28.31% of total detected metabolites 3 h after an acute intake
of 500 mg of an elderberry extract by post-menopausal women. Concentrations of PCA sulfates
determined at 3 h after intake were 2014
respectively, higher than those of PCA glucuronides (495
±
1765 nM/mM creatinine and 358 nM in urine and plasma,
190 nM/mM creatinine and 29 nM) and
±
non-conjugated PCA (1534 ± 1232 nM/mM creatinine and 24 nM) [8].
Different biological and pharmacological activities have been ascribed to PCA, including
antioxidant, antimicrobial, anticancer, antiulcer, antidiabetic, antiaging, anti-inflammatory,
and analgesic properties, as well as cardiovascular, hepatic, neurological, and nephron protective
effects [11,12]. As for PCA sulfates, some authors have reported anti-inflammatory effects in in vitro
assays. Thus, PCA sulfates have been shown to reduce the production of proinflammatory biomarkers of
coronary risk, such as interleukin-6 (IL-6) [17] and soluble vascular cell adhesion molecule-1 (VCAM-1)
in human endothelial cells [17,18]. In addition, PCA-3-sulfate was demonstrated to significantly reduce
liposaccharide induced tumor necrosis factor alpha (LPS-TNF-α) secretion and decrease interleukin-1
beta (IL-1β) in THP-1 monocytes [19].
A common problem when studying the effects and activity of conjugated metabolites of phenolic
compounds, such as PCA sulfates, is the usual lack of commercial standards, so they must be prepared
in the laboratory. Procedures for the chemical hemisynthesis of sulfates of different hydroxybenzoates
that are common metabolites of flavonoids, including protocatechuic acid, were previously described
by Zhang et al. [20] and Almeida et al. [21]. The method by Zhang et al. [20] involved the selective
protection of hydroxyl groups in the form of benzyl esters or tert-butyldimethylsilyl ethers and further
sulfation with trichloroethyl (TCE) chlorosulfate; finally, the protecting groups (TCE, benzyl, silyl)
were removed by hydrogenation under mild reducing conditions and in HF-pyridine in THF to yield
the corresponding sulfate derivatives. Sulfate derivatives were synthesized by Almeida et al. [21
]
by reaction of phenolic precursors with sulfur trioxide-pyridine in anhydrous pyridine and further
purified on a Dowex 50W-X8 ion-exchange resin. The products were then converted into their sodium
salts to improve their stability.
In the present study, another feasible and easily reproducible method using sulfur trioxide-
N-triethylamine as sulfation reagent was proposed for the preparation of PCA sulfates. Furthermore,
UV absorption and mass spectral characteristics, NMR data for their structural characterization, as well
as information about their stability are provided. This knowledge is expected to contribute to the
correct identification of these metabolites in biological samples. Furthermore, the proposed procedure
can be used for the preparation of PCA sulfates in view of their employment in studies on their
biological activity and mechanisms of action.

Molecules 2019, 24, 307
3 of 9
2. Results and Discussion
2.1. Preparation of PCA Sulfates
PCA sulfates were prepared via the reaction of the precursor phenolic acid with sulfur
trioxide-N-triethylamine, based on a method previously described for the preparation of flavonoid
sulfates [22]. The reaction was kept for 3 h, at which it was verified that the formation of the sulfates
reached their maximum, as checked by HPLC. The obtained chromatograms showed a not-well
resolved mixture of peaks presenting pseudomolecular ions [M
with PCA disulfates and monosulfates, respectively, together with some remaining PCA ([M
m/z 153).
−
H]− at m/z 313 and 233, coherent
−
H]− at
Semipreparative HPLC of this crude mixture allowed obtaining different fractions with a mixture
of the two monosulfates in different proportions, but none of them contained a single compound.
The close elution and difficult chromatographic separation of PCA-3-sulfate and PCA-4-sulfate have
also been noticed by other authors [8,10,16,21]. Fractions containing the monosulfates were pooled to
a unique fraction, which was concentrated and passed through an ion exchange cartridge, Oasis MCX,
to remove residual trimethylamine; the sulfates were further converted into their sodium salts and
freeze-dried. Finally, 128 mg of a clean fraction containing the two PCA monosulfates was obtained as
sodium salts, which represented a final yield of 15.5%. Figure 1 shows the HPLC chromatogram of the
obtained extract.
Figure 1. HPLC chromatogram recorded at 250 nM corresponding to the mixture of protocatechuic
acid (PCA) monosulfates obtained after semipreparative HPLC fractionation. Peak identification:
(1) PCA-4-sulfate, and (2) PCA-3-sulfate.
Compared to previously described procedures for the synthesis of benzoic acid sulfates [20,21],
the method proposed herein is faster and simpler, and it only involves one reaction step. A different
sulfation reagent (i.e., sulfur trioxide-N-triethylamine) is employed and the use of pyridine is avoided,
making it safer and facilitating the removal of the solvent and reagent excess. In preliminary assays
carried out to optimize the method, it was also checked that partial losses of the products were
produced during the elimination of pyridine, when it was used as a solvent, as also reported by
Almeida et al. [21].
2.2. Absorption and Mass Spectral Characteristics
ESI/MS analysis of peaks 1 and 2 confirmed that they had the same pseudomolecular ion [M − H]−
at m/z 233, corresponding to PCA monosulfates, and also showed the same MS2 fragmentation pattern
yielding product ions at m/z 189, 153, and 109. The ion at m/z 189 can be attributed to the loss of CO2
([M
−
H
−
44]−) from the carboxyl group of the PCA, indicating that this functional group was not

Molecules 2019, 24, 307
4 of 9
substituted and allowing the confirmation of the phenolic hydroxyl groups as location for the sulfate
moieties. The fragment at m/z 109 was due to the further loss of the sulfate group ([M 44
80]−)
(Figure 2). For both compounds, the main MS2 fragment was at m/z 153 (PCA) from the loss of the
sulfate group ([M
80]−), but there were some differences in the relative abundance among the
−
H
−
−
−
H
−
distribution of the other two fragment ions. For peak 1, the abundance of ion at m/z 109 was 74%, and
at m/z 189 was 5%, while for peak 2 the abundance of ion at m/z 109 was 78% and at m/z 189 was 4%.
Interestingly, the two peaks also possessed different UV spectra (Figure 3). Peak 1 presented two bands
of maximum absorption at 242 nM and 294 nM, whereas peak 2 showed λmax at 254 nM. The existence
of different fragmentation behavior and spectral shapes are characteristic features that might allow the
assignment of peak identities in a given sample with unknown composition.
Figure 2. MS2 fragmentation of the PCA monosulfates (pseudomolecular ion [M − H]− at m/z 233).
Figure 3. UV spectra of peaks 1 (A) and 2 (B) in the chromatogram of Figure 1.

Molecules 2019, 24, 307
5 of 9
2.3. NMR Analysis
The nMR spectrum of the PCA monosulfates mixture showed two series of analogous peaks,
with two doublets and one singlet for each series. The COSY, HMQC and HMBC plots (see Figures S1–S3,
included as supplementary information) did not show interactions between the two series of peaks,
1
which confirmed the existence of two different compounds. H and 13C-NMR data and assignments
of the displacements of the protons and carbons in each position of the aromatic ring, made based
1
on the two-dimensional spectra H-13C HMBC and HSQC, are shown in Table 1. The obtained
results agreed with data predicted by the Perkin Elmer ChemDraw Professional 16.0.1.4 (77) software,
with minor modifications in the displacement of the protons in position 2 for PCA-3-sulfate and in
position 5 for PCA-4 sulfate. This difference was explained by the influence of the adjacent sulfate
group, which has free rotation and can adopt a conformation in which the interaction is greater than
theoretically expected. The major compound was assigned to PCA-3-sulfate, for which it was found
that the proton in position 2 appeared at 7.76 ppm, undergoing a more significant shift to a lower
field than would theoretically be expected (6.85 ppm), while the proton H5 did not change over the
expected displacement. In the minority compound, PCA-4-sulfate, proton H5 underwent a lower field
displacement (7.14 ppm) than theoretically expected (6.85 ppm), which could be explained by the
interaction of the adjacent sulfate group. The two sulfates showed a proportion of 1:2.5, as determined
by nMR. The identification of PCA-3-sulfate as the major compound allowed it to be assigned to the
peak 2, which showed the largest area in the chromatogram of Figure 1; consequently, PCA-4-sulfate,
the compound with lower nMR signal, was assigned to peak 1.
Table 1. 1H and 13C-NMR data and HMBC correlations obtained for PCA-3-sulfate, and PCA-4 sulfate
determined in deuterated DMSO.
Position. δ 1H (ppm); m; J (Hz)
δ
13C (ppm)
HMBC
PCA-3-Sulfate
1
2
3
4
5
6
125.2
124.1
140
152.3
116.2
126.5
169
H2, H5
H6
H2, H5, H6
H2, H5, H6
H6
7.76, s *
6.80, d, J = 8.0
7.50, d, J = 8.4
H2, H5
H2, H6
Carbonyl
PCA-4-Sulfate
1
2
3
4
5
6
148.1
118.1
148.1
143.2
121.4
120.7
169
H2, H5
H6
H5, H2
H2, H6, H5
7.40, s
7.14, d, J = 9.2
7.31, d, J = 9.8
H2
H2, H6
Carbonyl
s *, singlet; d, doublet.
2.4. Stability of the Freeze-Dried Sulfates
The prepared compounds were freeze-dried and stored in a desiccator at room temperature for
three months. On days 1, 15, 30, 60, and 90, 2 mg of the preparation was weighed and dissolved
in ultrapure water to obtain a final concentration of 0.1 mg/mL and analyzed by HPLC to check
stability. According to the peak areas recorded at 250 nM (Table 2), it can be considered that the
freeze-dried compounds only kept reasonable stability for around 15 days (88% of the initial peak
area for PCA-4-sulfate and 85% for PCA-3-sulfate) to then fell quickly, losing up to 98% of their initial
concentration at day 30 of storage. This loss was mainly attributed to the cleavage of the sulfate moiety

Molecules 2019, 24, 307
6 of 9
to release PCA, as observed in the chromatograms. The stability of both compounds was very similar
between them.
Table 2. Evolution of the areas (mAU) of the chromatographic peaks of PCA-4-sulfate and PCA-3-sulfate
recorded at 250 nM over 3 months of storage of the freeze-dried compound at room temperature.
Time (days)
PCA-4-Sulfate (mAU)
PCA-3-Sulfate (mAU)
1
1203.6 (100% *)
1062.3 (88%)
23.4 (2%)
5940.4 (100%)
5095.5 (85%)
163.8 (2.7%)
123.6 (2%)
15
30
60
90
18 (1.5%)
0 (0%)
132.3 (2.2%)
* in brackets it is indicated the percentage of peak area relative to day 1.
3. Materials and Methods
3.1. Standards and Reagents
Protocatechuic acid (PCA), dioxane, trifluoroacetic acid (TFA), acetonitrile, and sulfur trioxide-
N-triethylamine were purchased from Sigma-Aldrich (Darmstadt, Germany). Methanol was
purchased from Macron Fine ChemicalsTM (Gliwice, Poland), formic acid and ammonia from VWR
(Fontenay-sous-Bois, France), and sodium hydroxide from Panreac (Barcelona, Spain).
3.2. Preparation of PCA Sulfates
The procedure was based on the method previously described in our laboratory for the
hemisynthesis of catechin sulfates [22] with modifications. PCA (500 mg) was dissolved in dioxane
(50 mL) and allowed to react with a 10-fold molar excess of sulfur trioxide-N-triethylamine. The reaction
was carried out under an argon atmosphere in a water bath (40 ◦C) for 3 h. The sulfation products
precipitated out and the supernatant was decanted. The precipitate was re-dissolved in ultrapure
water and dried on a rotary evaporator. The composition of the extract containing a sulfate mixture
was analyzed by HPLC-DAD-MS, as described in Section 3.3. Products of sulfation were newly
recovered in a minimal volume of ultrapure water, and PCA monosulfates were further fractionated
by semi-preparative HPLC, as described below. The fractions containing the monosulfates were
collected, concentrated, and re-dissolved in 2% formic acid in ultrapure water and loaded into an ion
exchange cartridge, Oasis MCX 3 cc (60 mg), to remove residual trimethylamine. The cartridges were
conditioned with methanol and equilibrated with ultrapure water; the sample was loaded and eluted
with 2% formic acid in ultrapure water, and the sulfates were collected in this step. For greater stability,
the sulfates were converted into their sodium salts as described by Almeida et al. [21], with 0.5 M
sodium hydroxide, and freeze-dried. The identity and purity of the compounds were checked by nMR,
as described below. The stability of the freeze-dried compounds was evaluated by HPLC from the
areas of their chromatographic peaks recorded at 250 nM for 3 months.
3.3. HPLC-DAD-MS Analyses
An Agilent 1200 series HPLC system (Agilent Technologies, Palo Alto, CA, USA) provided
with a quaternary pump and a diode array detector (DAD) and controlled by the ChemStation
software (version B.04.01) was used. The column was an Agilent Poroshell 120 EC-C18, 2.7 µm
(
4.6 mm × 150 mm) thermostatted at 35 ◦C. Solvents were (A) 0.1% formic acid in ultrapure water,
and (B) acetonitrile, establishing the following elution gradient: 100% A in 10 min, 0–5% B in 10 min,
5–10% B in 15 min, 10–14.5% B in 20 min, and 14.5–60% B in 15 min, at a flow rate of 0.5 mL/min.
Double detection was carried out in the diode array spectrophotometer and by mass spectrometry
(MS), using 250 and 290 nM as preferred wavelengths for chromatogram recording. MS detection
was performed on an API 3200 Qtrap (Applied Biosystems, Darmstadt, Germany) equipped with an

Molecules 2019, 24, 307
7 of 9
electrospray ionization probe (ESI) and a triple quadrupole mass analyzer that could also act as an ion
trap, controlled by Analyst 5.1 software. Mass spectra were recorded in negative ion mode between
m/z 100 and 900. Zero air at 50 psi was used as a nebulizer, turbo gas at 500 ◦C and 40 psi for the
elimination of the eluent, and nitrogen at 25 psi as a curtain and medium-collision gas. The method
of full scan at high sensitivity (Enhanced MS, EMS) was used for data acquisition, followed by an
analysis in Enhanced Product Ion (EPI) mode to obtain the characteristic fragmentation of the majority
ion obtained in the first experiment. The EMS parameters were as follows: capillary voltage,
de-clustering potential (DP), 65 V; entrance potential (EP), 10 V; and collision energy (CE),
8 V; CE, 50 V; and collision energy spread
−
3500 V;
−
−
−
20 V.
The conditions in the EPI mode were: DP,
(CES), 20 V.
−
40 V; EP,
−
−
3.4. Semipreparative HPLC
The separation was performed with an Agilent 1260 Infinity LC equipment (Agilent Technologies,
Waldbronn, Germany), consisting of a thermostatted autosampler, a binary system with two coupled
preparative pumps, a diode array detector, and a collector thermostatic sampling, controlled by the
OpenLab CDS Chemstation Workstation software (version C.01.04). An Agilent Prep-C18 column,
5
µ
m (21.2 mm
×
150 mm) was used. The solvents were (A) 0.05% trifluoroacetic acid in ultrapure
water, and (B) acetonitrile. The elution gradient was 100% A for 30 min, 0–5% B 10 min, 5–10% B for
20 min, 10–60% B for 5 min, using a flow rate of 15 mL/min. Chromatograms were acquired at 290 nM
for peak collection.
3.5. NMR Analysis
1
The H nMR (400 MHz) and 13C-NMR (100 MHz) spectra of the isolated metabolites were
measured in deuterated DMSO on a Bruker Avance DRX-400 spectrometer (Bruker Biospin GmbH,
Rheinstetten, Germany) at 298 K. The resonances at 2.50 ppm of the residual in the 1H spectra and at
1
39.79 ppm for deuterated DMSO in the 13C spectra were used as internal references. H chemical shifts
were assigned using one-dimensional (1D) and two-dimensional (2D) 1H nMR (correlation spectroscopy
(COSY)), while 13C resonances were assigned using 2D nMR (heteronuclear multiple-bond correlation
(HMBC) and heteronuclear multiple-quantum coherence (HMQC)). COSY, HMQC and HMBC plots
are included as supplementary information in Figures S1–S3, respectively.
4. Conclusions
Protocatechuic acid monosulfates were synthesized, isolated, and characterized by HPLC-DAD-
ESI/MS and nMR. Two compounds were obtained that were identified as PCA-4-sulfate and
PCA-3-sulfate, respectively, based on their nMR and mass spectral characteristics. Compared to
previously described procedures, the hemisynthesis method proposed herein is simpler, involving only
a reaction step. The sulfation reagent (sulfur trioxide-N-triethylamine) and solvent used are easier to
remove and safer, and the reaction kinetics is faster. The prepared metabolites are of great interest
for their use in in vivo and in vitro studies, to contribute to the knowledge of the compounds and
mechanisms involved in the biological effects of dietary polyphenols. The prepared PCA-sulfates and
data that contributed to their analytical features, such as their differential MS fragmentation behavior
and UV spectra, are also helpful as analytical standards for the identification of phenolic metabolites in
samples of unknown composition.
Supplementary Materials: Supplementary nMR data are included in Figures S1–S3.
Author Contributions: S.M.G.-Z. and S.G.-M. performed the experiments and analyzed data; J.J.P.-A.
performed nMR studies; A.M.G.-P. and C.S.-B. conceived and designed the study; and S.M.G.-Z. and C.S.-B.
discussed the results and wrote the manuscript. All the authors have read and approved the final version.

Molecules 2019, 24, 307
8 of 9
Funding: Financial support for this work was obtained from the Spanish Government through the
project AGL2015-64522-C2-R, from the FEDER-Interreg España-Portugal Program through the project
0377_IBERPHENOL_6_E and from Consejo Nacional de Ciencia y Tecnolog
ía (CONACYT, México) through a
predoctoral fellowship to author S.M.G.Z.
Conflicts of Interest: The authors declare no conflict of interest.
References
1.
Crozier, A.; Jaganath, I.B.; Clifford, M.N. Dietary phenolics: Chemistry, bioavailability and effects on health.
Food Funct. 2009, 26, 1001–1043. [CrossRef] [PubMed]
Vald s, L.; Cuervo, A.; Salazar, N.; Ruas-Madiedo, P.; Gueimonde, M.; Gonz
2.
é
ález, S. The relationship between
phenolic compounds from diet and microbiota: Impact on human health. Food Funct. 2015, 6, 2424–2439.
[CrossRef] [PubMed]
3.
4.
5.
6.
Tomas-Barberan, F.A.; Selma, M.V.; Espín, J.C. Interactions of gut microbiota with dietary polyphenols and
consequences to human health. Curr. Opin. Clin. Nutr. Metab. Care 2016, 19, 471–476. [CrossRef] [PubMed]
Williamson, G.; Clifford, M.N. Role of the small intestine, colon and microbiota in determining the metabolic
fate of polyphenols. Biochem. Pharmacol. 2017, 139, 24–39. [CrossRef] [PubMed]
Rechner, A.R.; Kuhnle, G.; Bremner, P.; Hubbard, G.P.; Moore, K.P.; Rice-Evans, C.A. The metabolic fate of
dietary polyphenols in humans. Free Radic. Biol. Med. 2002, 33, 220–235. [CrossRef]
Serra, A.; Macià, A.; Romero, M.A.; Reguant, J.; Ortega, N.; Motilva, M.J. Metabolic pathways of the colonic
metabolism of flavonoids (flavonols, flavones and flavanones) and phenolic acids. Food Chem. 2012, 130,
383–393. [CrossRef]
7.
Czank, C.; Cassidy, A.; Zhang, Q.; Morrison, D.J.; Preston, T.; Kroon, P.A.; Botting, N.P.; Kay, C.D. Human
metabolism and elimination of the anthocyanin, cyanidin-3-glucoside: A 13C-tracer study. Am. J. Clin. Nutr.
2013, 97, 995–1003. [CrossRef] [PubMed]
8.
9.
De Ferrars, R.M.; Cassidy, A.; Curtis, P.; Kay, C.D. Phenolic metabolites of anthocyanins following a dietary
intervention study in post-menopausal women. Mol. Nutr. Food Res. 2014, 58, 490–502. [CrossRef] [PubMed]
De Ferrars, R.M.; Czank, C.; Zhang, Q.; Botting, N.P.; Kroon, P.A.; Cassidy, A.; Kay, C.D. The pharmacokinetics
of anthocyanins and their metabolites in humans. Br. J. Pharmacol. 2014, 171, 3268–3282. [CrossRef] [PubMed]
10. Pimpão, R.C.; Ventura, M.R.; Ferreira, R.B.; Williamson, G.; Santos, C.N. Phenolic sulfates as new and highly
abundant metabolites in human plasma after ingestion of a mixed berry fruit purée. Br. J. Nutr. 2015, 113,
454–463. [CrossRef] [PubMed]
11. Kakkar, S.; Bais, S. A review on protocatechuic acid and its pharmacological potential. ISRN Pharmacol. 2014
,
2014, 952943. [CrossRef] [PubMed]
12. Khan, A.K.; Rashid, R.; Fatima, N.; Mahmood, S.; Mahmood, S.; Mir, S.; Khan, S.; Jabeen, N.; Murtaza, G.
Pharmacological activities of protocatechuic acid. Acta Pol. Pharm. 2015, 72, 643–650. [PubMed]
13. Masella, R.; Santangelo, C.; D’Archivio, M.; LiVolti, G.; Giovannini, C.; Galvano, F. Protocatechuic acid and
human disease prevention: Biological activities and molecular mechanisms. Curr. Med. Chem. 2012, 19,
2901–2917. [CrossRef] [PubMed]
14. Crozier, A.; Del Rio, D.; Clifford, M.N. Bioavailability of dietary flavonoids and phenolic compounds.
Mol. Asp. Med. 2010, 31, 446–467. [CrossRef]
15. Del Rio, D.; Rodriguez-Mateos, A.; Spencer, J.P.; Tognolini, M.; Borges, G.; Crozier, A. Dietary (poly)phenolics
in human health: Structures, bioavailability, and evidence of protective effects against chronic diseases.
Antioxid. Redox Signal. 2013, 18, 1818–1892. [CrossRef] [PubMed]
16. Pimpão, R.C.; Dew, T.; Figueira, M.E.; McDougall, G.J.; Stewart, D.; Ferreira, R.B.; Santos, C.N.; Williamson, G.
Urinary metabolite profiling identifies novel colonic metabolites and conjugates of phenolics in healthy
volunteers. Mol. Nutr. Food Res. 2014, 58, 1414–1425. [CrossRef]
17. Amin, H.P.; Czank, C.; Raheem, S.; Zhang, Q.; Botting, N.P.; Cassidy, A.; Kay, C.D. Anthocyanins and their
physiologically relevant metabolites alter the expression of IL-6 and VCAM-1 in CD40L and oxidized LDL
challenged vascular endothelial cells. Mol. Nutr. Food Res. 2015, 59, 1095–1106. [CrossRef]
18. Warner, E.F.; Zhang, Q.; Raheem, K.S.; O’Hagan, D.; O’Connell, M.A.; Kay, C.D. Common phenolic metabolites
of flavonoids, but not their unmetabolized precursors, reduce the secretion of vascular cellular adhesion
molecules by human endothelial cells. J. Nutr. 2016, 146, 465–473. [CrossRef]

Molecules 2019, 24, 307
9 of 9
19. Di Gesso, J.L.; Kerr, J.S.; Zhang, Q.; Raheem, S.; Yalamanchili, S.K.; O’Hagan, D.; Kay, C.D.; O’Connell, M.A.
Flavonoid metabolites reduce tumor necrosis factor- secretion to a greater extent than their precursor
α
compounds in human THP-1 monocytes. Mol. Nutr. Food Res. 2015, 59, 1143–1154. [CrossRef]
20. Zhang, Q.; Raheem, K.S.; Botting, N.P.; Slawin, A.M.Z.; Kay, C.D.; O’Hagan, D. Flavonoid metabolism:
The synthesis of phenolic glucuronides and sulfates as candidate metabolites for bioactivity studies of dietary
flavonoids. Tetrahedron 2012, 68, 4194–4420. [CrossRef]
21. Almeida, A.F.; Santos, C.N.; Ventura, M.R. Synthesis of new sulfated and glucuronated metabolites of
dietary phenolic compounds identified in human biological samples. J. Agric. Food Chem. 2017, 65, 6460–6466.
[CrossRef] [PubMed]
22. Gonzalez-Manzano, S.; González-Paramás, A.; Santos-Buelga, C.; Dueñas, M. Preparation and
characterization of catechin sulfates, glucuronides, and methylethers with metabolic interest. J. Agric.
Food Chem. 2009, 57, 1231–1238. [CrossRef] [PubMed]
Sample Availability: Samples of the compounds are available from the authors under request.
©
2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).